Drug Profile
ACP 319
Alternative Names: ACP319Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Acerta Pharma
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II B-cell lymphoma
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO)
- 01 Jun 2018 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in B-cell lymphoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
- 31 Mar 2017 ACP 319 is still in phase I trials for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO)